Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant
Malaria Journal, Volume 6, Article 35, Year 2007
Notification
URL copied to clipboard!
Description
Background. Plasmodium falciparum is the predominant human malaria species in Mozambique and a lead cause of mortality among children and pregnant women nationwide. Sulphadoxine/pyrimethamine (S/P) is used as first line antimalarial treatment as a partner drug in combination with artesunate. Methods. A total of 92 P. falciparum-infected blood samples, from children with uncomplicated malaria attending the Centro de Saude de Bagamoyo in the Province of Maputo-Mozambique, were screened for S/P resistance-conferring mutations in the pfdhfr and pfdhps genes using a nested mutation-specific polymerase chain reaction and restriction digestion (PCR-RFLP). The panel of genetic polymorphisms analysed included the pfdhfr 164L mutation, previously reported to be absent or rare in Africa. Results. The frequency of the S/P resistance-associated pfdhfr triple mutants (51I/59R/108N) and of pfdhfr/pfdhps quintuple mutants (51I/59R/108N + 437G/540E) was 93% and 47%, respectively. However, no pfdhfr 164L mutants were detected. Conclusion. The observation that a considerably high percentage of P. falciparum parasites contained S/P resistance-associated mutations raises concerns about the validity of this drug as first-choice treatment in Mozambique. On the other hand, no pfdhfr 164L mutant was disclosed, corroborating the view that that this allele is still rare in Africa. © 2007 Fernandes et al; licensee BioMed Central Ltd.
Authors & Co-Authors
Fernandes, Natércia
Mozambique, Maputo
Universidade Eduardo Mondlane Faculdade de Medicina
Figueiredo, Paula
Portugal, Lisbon
Instituto de Higiene e Medicina Tropical
do Rosário, Virgílio Estólio
Portugal, Lisbon
Instituto de Higiene e Medicina Tropical
Cravo, Pedro Vítor Lemos
Portugal, Lisbon
Instituto de Higiene e Medicina Tropical
Statistics
Citations: 18
Authors: 4
Affiliations: 2
Identifiers
Doi:
10.1186/1475-2875-6-35
e-ISSN:
14752875
Research Areas
Cancer
Genetics And Genomics
Infectious Diseases
Maternal And Child Health
Study Locations
Mozambique
Participants Gender
Female